Showing results (141-150 of 233) with videos related to

Sort By:
Pageof 24
Blood|September 27, 2007
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989Bart Barlogie, Guido Tricot, Jeff Haessler, et al.
Journal of Clinical Pathology|February 20, 2024
Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related diseaseAsami Nishikori, Midori Filiz Nishimura, David C Fajgenbaum, et al.
American Journal of Hematology|July 15, 2021
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman diseaseYoshito Nishimura, David C Fajgenbaum, Sheila K Pierson, et al.
The New England Journal of Medicine|March 10, 2006
Thalidomide and hematopoietic-cell transplantation for multiple myelomaBart Barlogie, Guido Tricot, Elias Anaissie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
British Journal of Haematology|October 28, 2008
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantationJumei Shi, Guido Tricot, Susann Szmania, et al.
Blood|May 18, 2006
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantationIchiro Hanamura, James P Stewart, Yongsheng Huang, et al.
JAMA Oncology|June 5, 2025
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical TrialsSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Oncotarget|February 19, 2019
Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53Cody Ashby, Ruslana G Tytarenko, Yan Wang, et al.
British Journal of Haematology|April 15, 2025
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world dataNoa Biran, Binod Dhakal, Ruben Niesvizky, et al.
Pageof 24